Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (897)	11/23/2005 6:48:48 PM
From: richardred	Respond to of 7256

Paul: I should also mention the little used pac-man defense is also a possible risk in this case. In witch case Mentor would be put into play. The last notable time I remember that successful defense. When William Agee of Bendix offered to buy Martin-Marietta.

To: richardred who wrote (897)	12/6/2005 9:57:05 AM
From: richardred	Respond to of 7256

Inamed says Allergan deal superior to Medicis offer Tue Dec 6, 2005 09:28 AM ET CHICAGO, Dec 6 (Reuters) - Breast implant maker Inamed Corp. said on Tuesday said it received a revised offer from Botox-maker Allergan Inc.(AGN.N: Quote, Profile, Research) that is superior to its prior merger agreement with wrinkle treatment maker Medicis Pharmaceutical Corp.(MRX.N: Quote, Profile, Research) Inamed said its board has determined Allergan's transaction is fair and superior to the Medicis deal. Inamed, however, said it is remaining neutral and is not making any recommendation to shareholders. Allergan in a separate statement, said it has talked with U.S. antitrust officials about a plan to divest Reloxin, a key Inamed product to smooth wrinkles. yahoo.reuters.com

To: richardred who wrote (897)	12/9/2005 11:51:25 AM
From: richardred	Read Replies (1) \| Respond to of 7256

These guys are looking for Medicis to sweeten! With nearly a 10% stake, why wouldn't they. U.S. hedge fund says undecided on Allergan bid for Inamed Thu Dec 8, 2005 12:43 PM ET NEW YORK, Dec 8 (Reuters) - S.A.C. Capital Advisors, a $6 billion hedge fund manager that controls a 9.5 stake in medical devices maker Inamed Corp. (IMDC.O: Quote, Profile, Research) , on Thursday said it was undecided as to whether to support Allergan Inc.'s (AGN.N: Quote, Profile, Research) $3.2 billion offer for the company. S.A.C., which is managed by Steven A. Cohen, said in a regulatory filing that it is "reviewing" Allergan's offer, but that it has not decided whether to support it. Irvine, California-based Allergan offered to buy Inamed for $84 in cash or .8498 of a share of Allergan stock. Inamed has a previous agreement to be bought by Medicis Pharmaceutical Corp. (MRX.N: Quote, Profile, Research) for $2.5 billion, but it said on Tuesday that it has determined that the Allergan offer is "superior," which typically allows a company to terminate a previous agreement. Inamed could increase its bid in the next few days, said CIBC World Markets analyst John Calcagnini in a research note on Thursday. Calcagnini said the move would put revised terms in front of Inamed shareholders in time for the Dec. 19 proxy vote. Inamed shares were trading up $1.11 to $87.46, or 1.2 percent, on midday Nasdaq trading, while Allergan shares were trading up $1.51, or 1.4 percent, to $108.36 on the New York Stock Exchange. yahoo.reuters.com